Global Plasma Therapeutics Market Size By Type (Human Serum Protein, Plasma-Derived Clotting Factor), By Application (Research Laboratories And Institutions, Hospitals), By Region, And Segment Forecas...

The Global Plasma Therapeutics Market was valued at USD 32.4 billion in 2023 and is projected to surpass USD 55.7 billion by 2031, expanding at a CAGR of 7.3% during the forecast period from 2023 to 2031. This growth is driven by the rising demand for plasma-derived therapies due to increasing cases of immunodeficiency disorders, hemophilia, and other rare chronic conditions. With continued technological advancements and expanding healthcare access in emerging economies, plasma therapeutics have become essential in both life-saving and maintenance therapies across a wide range of medical specialties.

Drivers

1. Increasing Prevalence of Chronic Diseases and Rare Disorders

Growing incidences of primary immunodeficiency diseases (PIDs), neurological disorders, and bleeding disorders like hemophilia are key drivers. These conditions rely heavily on immunoglobulins and clotting factors derived from plasma.

2. Expansion of Plasma Collection and Processing Capabilities

Investments in plasma collection centers and advances in fractionation technology are enhancing the supply chain efficiency, thus boosting market growth.

3. Rising Demand for Immunoglobulin-Based Therapies

The immunoglobulin segment continues to dominate due to its wide application in treating neurological, hematological, and autoimmune diseases, further supported by favorable reimbursement policies in developed nations.

Restraints

1. High Cost and Lengthy Manufacturing Process

Plasma therapeutic production is time-intensive and costly, involving sophisticated infrastructure for collection, testing, and fractionation. These factors pose entry barriers for new players and hinder accessibility in low-resource settings.

2. Stringent Regulatory and Compliance Requirements

Tight regulatory frameworks regarding donor screening, pathogen testing, and clinical validations can slow down product approvals and market entry.

Opportunity

1. Emerging Markets with Growing Healthcare Infrastructure

Rapid improvements in healthcare access and awareness in Asia-Pacific and Latin America present untapped potential for plasma therapies.

2. Innovation in Recombinant and Hybrid Therapies

Biotechnology advancements are paving the way for hybrid plasma-derived and recombinant therapies that promise improved safety and efficacy profiles.

Market by System Type Insights

Based on system type, the Immunoglobulin segment held the largest market share in 2023. Its wide therapeutic range across autoimmune, inflammatory, and immunodeficient conditions ensures high demand. Meanwhile, the Albumin segment is expected to witness the fastest growth, driven by its expanding application in liver disease, shock, burns, and surgical interventions.

Market by End-use Insights

The Hospitals & Clinics segment emerged as the leading end-use sector, accounting for more than 60% of the market in 2023. This dominance stems from the high volume of critical treatments administered in hospitals, including intravenous immunoglobulin infusions and coagulation therapy. Specialty pharmacies are also showing growth potential due to increasing at-home care and outpatient services.

Market by Regional Insights

North America dominated the plasma therapeutics market in 2023, driven by strong infrastructure for plasma collection, advanced healthcare systems, and high public awareness. However, Asia-Pacific is anticipated to grow at the fastest rate, with countries like China and India increasing investments in biotechnology, improving healthcare access, and launching awareness programs for rare diseases.

Competitive Scenario

Key players in the Global Plasma Therapeutics Market include:

Grifols, S.A.

CSL Behring

Takeda Pharmaceutical Company Limited

Octapharma AG

Kedrion Biopharma Inc.

Bio Products Laboratory Ltd.

ADMA Biologics

LFB Group

Sanquin

Green Cross Corporation

These companies are focusing on expanding plasma collection networks, acquiring regional players, and investing in R&D to enhance therapeutic capabilities.

Scope of Work – Global Plasma Therapeutics Market

Report Metric Details

Market Size (2023) USD 32.4 billion

Projected Market Size (2031) USD 55.7 billion

CAGR (2023-2031) 7.3%

Market Segments System Type (Immunoglobulin, Albumin, Coagulation Factors), End-use (Hospitals & Clinics, Specialty Pharmacies)

Growth Drivers Increasing prevalence of chronic & rare disorders, expanding plasma collection infrastructure, rising demand for immunoglobulin therapies

Opportunities Market expansion in emerging regions, innovations in recombinant and hybrid therapies

Key Market Developments

2023: CSL Behring announced the expansion of its plasma collection network with 25 new centers across North America.

2024: Grifols launched a next-gen immunoglobulin therapy with enhanced administration convenience.

2025: Takeda partnered